TPA
MRNA icon

Trivium Point Advisory’s Moderna MRNA Stock Holding History

Trivium Point Advisory’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,171
Closed -$327K – 205
2023
Q3 		$327K Sell
3,171
-17
-0.5% -$1.9K 0.09% 160
2023
Q2 		$387K Buy
3,188
+179
+6% +$23.9K 0.1% 162
2023
Q1 		$462K Buy
3,009
+385
+15% +$63.5K 0.12% 150
2022
Q4 		$473K Buy
2,624
+86
+3% +$14.1K 0.14% 144
2022
Q3 		$318K Buy
+2,538
New +$385K 0.1% 159

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Trivium Point Advisory's MRNA Position: Q4 2023 in Review

Trivium Point Advisory sold out of Moderna (MRNA) in Q4 2023, closing a stake of 3,171 shares — an estimated $327K sold.

Trivium Point Advisory first reported a position in MRNA in Q3 2022 and held it in 5 quarters. The position peaked at $473K in Q4 2022. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Trivium Point Advisory reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Trivium Point Advisory sold 3,171 Moderna shares in Q4 2023, an estimated $327K.
  • Trivium Point Advisory first reported a position in Moderna in Q3 2022 and held it in 5 quarters.
  • Trivium Point Advisory's Moderna position peaked at $473K in Q4 2022.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Trivium Point Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.